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Adjuvant Drugs to Local 
Anesthetics
Nandita Mehta and Sayyidah Aasima tu Nisa Qazi
Abstract
Local anesthetics have a potential to be used in a wide variety of situations 
including central neuraxial blocks, peripheral nerve blocks, intravenous, and local 
infiltration both for surgeries and acute and chronic pain management. Their use 
can be limited by their duration of action and the dose-dependent adverse effects 
on the cardiac and central nervous system. Adjuvants are drugs which, when co-
administered along with local anesthetic agents, improve the latency of onset and 
duration of analgesia and counteract disadvantageous effects of local anesthetics. 
There is a wide armamentarium of adjuvant drugs to choose to be added in neur-
axial and peripheral nerve blocks. They can be broadly divided into non-opioids 
and opioids, with non-opioids being vasoconstrictors, α2-adrenoceptor agonists, 
anti-inflammatory agents, acetylcholine esterase inhibitors (neostigmine), adenos-
ine, ketorolac, midazolam, magnesium, and sodium bicarbonate and opioids being 
lipophilic (fentanyl and sufentanil) and hydrophilic (morphine).
Keywords: local anesthetics, adjuvants, neuraxial blocks, peripheral nerve blocks, 
opioids, neurotoxicity
1. Introduction
Local anesthetics (LA) are widely used in clinical practice for regional anesthe-
sia or analgesia in various locations like central neuraxial blockade, peripheral nerve 
block, intravenously, and local infiltration. Infiltration with LA around the nerve 
produces analgesia by interrupting pain signals to the brain. The analgesic effect of 
a nerve block with LAs lasts only a few hours. Therefore, after surgery patients may 
suffer from moderate to severe acute pain. The duration of the action of LA can be 
prolonged by either increasing the dose or administering a continuous infusion of 
the drug, which can lead to dose-dependent side effects on the cardiovascular sys-
tem and/or central nervous system (CNS) [1, 2]. The popularity of peripheral nerve 
blocks for surgical anesthesia as well as for postoperative analgesia has increased 
significantly due to anesthetists becoming more familiar with ultrasound-guided 
techniques. While the use of catheters for continuous infusions allows for sustained 
pain relief during the perioperative period, they can increase the challenges related 
to patient management, catheter displacement, and the potential for increased 
infection risk. In the case a long-acting LA or continuous block is used, sensory 
block is also associated with prolonged motor block in the postoperative period. 
Prolonged motor blockade in the postoperative period is undesirable as it leads to 
delayed mobilization of the patient and hence increased risk of complications.
Local Anesthetics
2
The adjuvant drugs of regional LAs improve the quality and duration of anesthe-
sia and analgesia and patient safety, thus increasing patient satisfaction and comfort 
[3, 4]. The aim of this chapter is to discuss the past, present, and future trends in 
the use of adjuvants, as well as their benefits and side effects.
2. Adjuvants drugs
Adjuvants are drugs which, when administered along with LA agents, may 
improve the latency of onset and duration of analgesia and counteract the undesir-
able effects associated with large doses of LAs. The use of adjuvant drugs has the 
potential to improve the efficacy of peripheral and central neuraxial blocks and 
decrease LA systemic toxicity by chiefly prolonging the duration of sensory block, 
Opioids
• Morphine
• Pethidine
• Fentanyl
• Sufentanil
• Hydromorphone
• Buprenorphine
• Diamorphine
• Tramadol
Vasoactive agents
• Epinephrine
• Phenylephrine
Alpha-2 adrenergic agonists
• Clonidine
• Dexmedetomidine
Steroids
• Dexamethasone
Nonsteroidal anti-inflammatory drugs
• Parecoxib
• Lornoxicam
Other agents
• Ketamine
• Midazolam
• Neostigmine
• Droperidol
• Magnesium sulfate
• Sodium bicarbonate
• Potassium chloride
• Adenosine
• Dextran
Table 1. 
Classification of adjuvant drugs.
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enhancing motor blockade, and limiting the overall dose requirement of LAs. An 
ideal adjuvant should not only shorten the speed of onset of action of the LA drug 
but also reduce its dosage along with providing hemodynamic stability, optimal 
sedation, and minimum adverse effects.
A wide variety of adjuvant drugs have been used for both neuraxial and peripheral 
nerve blocks (Table 1). They can be broadly divided into non-opioids and opioids.
Current research is directed toward a search for agents and techniques which 
would prolong LA action while limiting its side effects and giving the patient its 
maximum benefit. These include techniques like the use of charged molecules to 
produce LA action (tonicaine and n-butyl tetracaine), newer delivery mechanisms 
for prolonged bioavailability (liposomal, cyclodextrin, and microsphere systems), 
and the use of other drugs (dextrans, adenosine, neuromuscular blockers) [3, 4].
While the use of LA adjuvants in regional anesthesia [5, 6] is in widespread 
clinical off-label use and has been subject to multiple clinical trials, we would like 
to emphasize on the fact that only a few adjuvants have been approved by the Food 
and Drug Administration (FDA), so absolute caution must be exercised while using 
these adjuvants.
3. Opioids
Opioids are the most common and the earliest used LA adjuvants. Their use in 
neuraxial and peripheral nerve blocks has evolved greatly over the last 30 years. It 
is advisable to use specific opioids, at appropriate doses and routes of administra-
tion that result in a primarily spinal site of action rather than a systemic opioid [7]. 
Afferent noxious stimuli from peripheral tissues converge in the dorsal horn of the 
spinal cord, where the primary nociceptive neuron synapses with the interneurons 
and the second-order nociceptive neuron in the spinothalamic tract. Blockade of 
these opioid receptors by agonists helps to suppress afferent nociceptive input 
from pain sites by modulating the release of pain-pathway associated peptides [8]. 
Opioids produce analgesia by mimicking the actions at specific receptors of endog-
enous opioid peptides. These peptides are beta-endorphin, met-enkephalin, and 
dynorphin. The three main types of opiate receptors, each with its own subtypes, 
are mu (μ), delta (δ), and kappa (ĸ) [9]. The most important target for opioids is 
the μ-receptor (endorphin), and intrathecal opioids appear to selectively modulate 
C- and A-fibers with minimal impact on dorsal root axons. The enkephalins are 
the primary endogenous ligands of the delta receptor and are involved with spinal 
analgesia. Dynorphin is the ligand for the kappa receptor. Activation of the kappa 
receptor results in segmental spinal analgesia and sedation. Most of the mixed 
agonist–antagonist opioids like butorphanol bind to the kappa receptor.
The exact mechanism of action of opioids at peripheral nerve is still uncertain. 
Evidences have begun to support the presence of peripheral opioid receptors [10]. 
The possible mechanism of prolonged analgesia by peripheral opioid administra-
tion could be through direct binding at opioid receptors of dorsal nerve root aided 
by axonal flow, diffusion through brachial plexus sheath to extradural or subarach-
noid space to dorsal horn, and central action after peripheral systemic uptake [11].
3.1 Morphine
The first opioid to be used intrathecally was morphine with the initial clinical 
study published in 1979 [12]. Morphine being relatively less hydrophobic than other 
opioids remains in the CSF for a longer time and therefore occupies the rostral 
receptor sites for a longer duration than other opioids [13]. Consequently, morphine 
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produces a long-lasting and adequate analgesia with intrathecal use [14]. However, 
this huge advantage is offset by the increased risk of adverse effects, especially post-
operative respiratory depression [15], which remains a particular concern among 
anesthetists. Intrathecal and epidural morphine are associated with a high incidence 
of side effects like nausea, vomiting, pruritus, urinary retention, sedation, and 
delayed respiratory depression [13, 16]. The recommended dose for intrathecal 
administration is 50–300 μg, while as 2–5 mg of epidural loading dose is considered 
adequate. The risk of side effects increases exponentially with the increase in the 
dose [16, 17].
3.2 Pethidine
Pethidine (meperidine) is a lipophilic phenylpiperidine derivate that is 30 times 
more lipid soluble and 10 times less potent than morphine, leading to a faster onset 
and a shorter duration of action than morphine. Pethidine possesses some local 
anesthetic properties (motor and sensory fiber block) which lets it stand out from 
the rest of the opioid agents. Pethidine is a popular choice for obstetric analgesia 
used mainly in epidural analgesia during labor. Intrathecal use of pethidine is 
not recommended. The incidence of nausea, vomiting, and hypotension is more 
with pethidine than with morphine. Pethidine can be injected as a loading dose of 
25–50 mg in the epidural space.
3.3 Fentanyl
In addition to acting on the spinal cord receptors and peripheral receptors, 
fentanyl is also reported to have a local anesthetic like action, but this requires a 
very high concentration (50 g/mL) which is not clinically feasible [18]. Fentanyl 
as an adjuvant to LA causes significant prolongation of duration of analgesia but 
delays the onset of both sensory and motor blockade compared to LAs alone [19]. 
The change in pH of the anesthetic solution resulting in slower penetration of nerve 
membrane by LA is considered to be responsible for this effect [20]. The recom-
mended intrathecal dose is 10–25 μg, and the epidural loading dose is 50–100 μg. 
Fentanyl as adjuvant does not prolong motor block, so it allows early ambulation, 
thereby reducing the morbidity. The duration of action is 2–4 h, and the risk of 
respiratory depression is very low and of short duration [17].
3.4 Sufentanil
A potent agonistic opioid was synthesized in the mid-1970s. A piperidine 
derivative is 6–10 times more potent than fentanyl, depending on the route of 
administration; it has been registered for intravenous, epidural, and subarachnoid 
administration. It is considered to be more lipid soluble than its counterparts, a bet-
ter μ receptor ligand. It is an extremely potent opioid with a faster onset of action 
than its counterparts. Its use in clinical practice is limited by its short duration of 
action and high side effect profile. The recommended intrathecal dose is 2.5–10 μg, 
and epidural loading dose is 10–50 μg [17].
3.5 Hydromorphone
This opioid has intermediate lipid solubility. Due to its hydrophilicity, epidural 
hydromorphone can cross the blood-brain barrier faster and provide fast onset and 
modest duration of action.
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3.6 Buprenorphine
Buprenorphine is a highly lipophilic partial opioid receptor agonist. It is also 
considered to have local-anesthetic-like capacity by blocking voltage-gated sodium 
channels. Buprenorphine and its metabolite nor-buprenorphine have been shown to 
act on κ and δ opioid receptors in addition to μ receptors which account for its anti-
hyperalgesic effects. The risk of side effects like postoperative nausea and vomiting 
(PONV) is more with the use of perineural buprenorphine [21].
3.7 Diamorphine
It is a diacetylated analogue of morphine with a potency of approximately 1.5–2 
times that of morphine. This leads to a faster onset and slightly shorter duration of 
action than morphine. It is a lipophilic semi-synthetic opioid and is a prodrug that 
is converted to its active metabolites (morphine and 6-monoacetyl morphine) by 
deacetylation in the liver and neural tissues. The recommended intrathecal dose is 
300–400 μg, and epidural loading dose is 2–5 mg [17, 22].
3.8 Tramadol
Tramadol is a weak centrally acting opioid. A potency ratio of oral morphine 
to oral tramadol has been reported to be between 1:4 and 1:10. It has been shown 
to have Na+ and K+ channel blocking properties and can block motor and nocicep-
tive signals similar to that of LAs. The central and peripheral analgesic effects of 
tramadol have not been fully explained, but it is a selective agonist of μ-receptors. 
Tramadol also prevents reuptake of noradrenaline and enhances both serotonin 
and noradrenaline release. The monoaminergic activity of tramadol increases the 
inhibitory activity of the descending pain pathways, resulting in a suppression of 
nociceptive transmission at the spinal level [23].
4. Vasoactive agents
Vasoactive drugs are the oldest adjuvants that have been used, although at the 
beginning their action was attributed more to the fact that their vasoconstric-
tor effect prolonged the anesthetic and analgesic results of LAs by decreasing 
the blood flow of the site where they were injected. Adrenaline was the first 
 vasopressor used.
4.1 Epinephrine
Epinephrine has been used along with LA in neuraxial and peripheral nerve 
blocks since Heinrich Braun first experimented with its use as a “chemical tourni-
quet” in the early 1900s [24]. Epinephrine potentiates the LA action. The substantia 
gelatinosa of the dorsal horn of the spinal cord houses alpha-2 adrenoreceptors 
wherein the epinephrine by its direct action mediates its antinociceptive properties 
resulting in presynaptic inhibition of transmitter release from Aδ and C fibers. 
Also its vasoconstrictive properties limit the systemic absorption of LA leading to 
prolonged duration of action. There are concerns about epinephrine being a potent 
vasoconstrictive agent can place the blood supply of the spinal cord at risk and may 
lead to ischemia of the spinal cord leading to permanent damage. Epinephrine is 
typically administered in doses of 0.2–0.3 mg [25].
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4.2 Phenylephrine
Phenylephrine has a mechanism of action similar to that of epinephrine. It has 
vasoconstrictive abilities, thus limiting the uptake of LA and prolonging their 
duration of action. Phenylephrine in the dose of 2–5 mg prolongs both lidocaine 
and tetracaine spinal anesthesia to a similar extent as epinephrine. The use of 
phenylephrine has declined in popularity because of its association with transient 
neurologic symptoms (TNS) [26].
5. Alpha-2 adrenergic agonists
Alpha-2 adrenergic receptor agonists have recently been the focus of interest 
for their sedative, analgesic, perioperative sympatholytic, anesthetic sparing, and 
hemodynamic stabilizing properties. The central α-2-AR agonists inhibit nocicep-
tive impulses by activating post-junctional α-2-adrenoceptors in the dorsal horn 
of the spinal cord. These receptors are located on primary afferent terminals (both 
at peripheral and at spinal endings), on neurons in the superficial lamina of the 
spinal cord, and within several brainstem nuclei responsible for analgesia. They 
block the conduction of C- and A-delta fibers and increase potassium conductance, 
thus intensifying conduction block. They also cause local vasoconstriction, thereby 
reducing vascular uptake of the LA from around the neural structures and in turn 
prolonging the duration of action [27–29].
5.1 Clonidine
Clonidine is an imidazole derivative with selective partial agonist properties 
which inhibit the nociceptive impulses by acting on the post-junctional alpha-2 adr-
enoreceptors in the dorsal horn of the spinal cord. In neuraxial blocks, it has a local 
effect leading to decreased sympathetic outflow, while in peripheral nerve blocks it 
prolongs the duration of analgesia by hyperpolarization of cyclic nucleotide-gated 
cation channels. Clonidine enhances and prolongs sensory and enhances motor 
blockade when used along with LA for epidural or peripheral nerve blocks [30]. 
The alpha-2 adrenergic agonists also enhance analgesia from intraspinal opioids by 
interactions with both pre- and post-synaptic receptors within the spinal cord.
Although there is no agreement on the doses of intrathecal clonidine [31], 
the most commonly used doses vary widely. The most recommended dose for 
intrathecal use is 15–150 μg, with the incidence of adverse effects (bradycardia, 
sedation, hypotension) increasing with doses above 150 μg. Clonidine can be used 
via epidural route with a bolus dose of 75–150 μg. In pediatric anesthesia, the use 
of clonidine (1 μg/kg) as an adjuvant along with LA for caudal blocks doubles the 
duration of analgesia when compared to LA alone but causes marked sedation [17].
Clonidine has been found to prolong the action of local anesthetics in peripheral 
blocks in the postoperative period. This effect of clonidine is dose-related. After 
brachial plexus block with mepivacaine, the minimum doses which significantly 
prolong analgesia and anesthesia are 0.1 and 0.5 μg/kg, respectively [32].
5.2 Dexmedetomidine
Dexmedetomidine is seven times more selective agonist to alpha-2 receptor than 
clonidine (seven times more specific for alpha-2 than alpha-1) but has a similar 
mechanism of blocking hyperpolarization-activated cation channels. When used 
as an adjuvant to LA for neuraxial block, dexmedetomidine leads to reduced onset 
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time of sensory and motor block, increased duration of sensory block, and delayed 
recovery from motor blockade. It leads to prolongation of postoperative analgesia, 
decreased requirement of additional analgesics, delayed first rescue analgesic, and 
decreased postoperative shivering. Dose in spinal anesthesia varies from 3 to 15 μg 
as an adjuvant to LA [33]. For caudal epidural block, 1–2 μg/kg of dexmedetomidine 
along with bupivacaine can lead to prolonged analgesia without significant side 
effects [34].
The most common reported adverse effects are bradycardia and hypotension. 
Bradycardia due to dexmedetomidine is resistant to atropine, and higher doses are 
needed; although rare, even cardiac arrest can occur.
It has been shown that clonidine and dexmedetomidine administered orally, 
intramuscularly, and intravenously also prolong the anesthetic effect of intrathecal 
LA [35–40].
6. Steroids: dexamethasone
Acute inflammation from tissue injury has an important role in surgical pain, 
and glucocorticoids may be useful for its anti-inflammatory effect. Johansson et al. 
[41] investigated the corticosteroid effect on the plantar nerve of rats finding that 
methylprednisolone suppresses transmission in thin unmyelinated C fibers but not 
in myelinated A-beta fibers. The effect was reversed when the corticosteroid was 
removed, suggesting a direct action in the membrane.
Dexamethasone-induced prolongation of peripheral nerve blockade follow-
ing LA injection is commonly attributed to its anti-inflammatory action. It also 
improves the quality and duration of analgesia over LAs alone. This is thought to 
be mediated by its capacity to alter the release of inflammatory mediators, reduce 
ectopic neuronal discharge, and inhibit potassium channel-mediated discharge of 
nociceptive C fibers [41]. Its action on glucocorticoid receptor is considered to alter 
the functioning of ion channels and produce acidosis around the nerve cell, thereby 
reducing the concentration of LA required to produce blockade of signal transmis-
sion or trapping the highly ionized bupivacaine molecule into the neuronal cell. 
Studies using dexamethasone for postoperative pain relief have produced positive 
results mainly in surgery involving large amounts of tissue trauma. A systematic 
review and meta-analysis included 1695 patients distributed in 29 controlled 
clinical trials where dexamethasone 4 and 8 mg perineural was used as adjuvant 
to LA. These authors found that dexamethasone increased the mean (95% CI) 
duration of analgesia by 233 (172–295) min when injected with short- or medium-
term action LA and by 488 (419–557) min when injected with long-term action 
LA, p < 0.00001 for both. However, these results should be taken with caution 
due to the great heterogeneity of results, with I2 exceeding 90% for both analysis. 
Meta-regression did not show an interaction between dose of perineural dexa-
methasone (4–10 mg) and duration of analgesia (r2 = 0.02, p = 0.54). There were 
no differences between 4 and 8 mg dexamethasone on subgroup analysis [42]. After 
reviewing the current literature, Wiesmann et al. [43] prefer a systemic application 
mode (intravenously) over a perineural route of dexamethasone administration as a 
complement to peripheral nerve blocks. A single dose of dexamethasone could be a 
useful complement to prolong peripheral nerve blocks. In a randomized controlled 
triple-blind crossover study in 24 male volunteers, the authors used ultrasound-
guided ulnar nerve blocks (ropivacaine 0.75% wt/vol, 3 ml, with saline 1 ml with 
or without dexamethasone 4 mg) which were performed on three occasions in each 
volunteer along with an IV injection of saline 1 ml with or without dexamethasone 
4 mg. The median [inter-quartile range (IQR)] duration of sensory block was 6.87 
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(5.85–7.62) h in the control group, 7.37 (5.78–7.93) h in the perineural group, and 7.37 
(6.10–7.97) h in the IV group (P = 0.61). There was also no significant difference in 
block onset time between the three groups. Dexamethasone 4 mg had no clinically 
significant effect on the duration of sensory block provided by ropivacaine applied 
to the ulnar nerve [44]. The role of dexamethasone as an adjunct in peripheral nerve 
blockades is still unclear.
7. Nonsteroidal anti-inflammatory drugs (NSAIDs)
Several studies have demonstrated that the presence of COX-2 receptors in 
the dorsal horn of the spinal cord could regulate spinal nociceptive transmission 
[45]. Some studies suggest that administering a COX-2 antagonist directly on the 
central or peripheral nerve might have a better analgesic profile than intravenous 
administration of the same drug [46]. Basically COX-2 inhibitors reduce inflamma-
tion and pain sensation by inhibiting prostaglandin production. However, the role 
of COX-2 in the central nervous system is of more importance. Inflammation can 
induce COX-2 production and will lead to the release of prostanoids that sensitize 
the peripheral nociceptor terminals and produce localized hyperalgesia. It is hence 
thought that the administration of COX-2 antagonist on spinal or peripheral nerves 
may be a more effective mode of pain relief than the intravenous or intramuscular 
route. There are very less studies on this subject. Further research and studies need 
to be conducted to verify the use of NSAIDs as adjuvants.
8. Miscellaneous agents
8.1 Ketamine
Ketamine is a noncompetitive antagonist of NMDA receptor that has been 
shown to have local anesthetic properties. Ketamine acts on more than one region. 
It has actions at monoaminergic receptors, opioid receptors, voltage-sensitive 
calcium channels, and muscarinic receptors, in addition to local anesthetic actions 
through sodium channel blockade. Systemic ketamine causes central summation 
in the second-order pain neuron and decreases severe pain [3, 47, 48]. Epidural 
administration of ketamine at 0.5–1 mg/kg has been shown to reduce intraopera-
tive and postoperative analgesic requirements without increased side effects [25]. 
Preservative-free S(+)-ketamine administered during caudal block for children at 
a dose of 0.5 mg/kg has been shown to extend analgesia time by several hours [17]. 
Intrathecal administration of ketamine is not recommended.
The risk of psychomimetic adverse effects such as hallucinations is a worrying 
factor for most anesthetists, limiting its use, but it can be easily overcome by using 
intravenous benzodiazepines as premedication prior to the block.
8.2 Midazolam
Midazolam, a water-soluble benzodiazepine, an indirect agonist of the gamma-
aminobutyric acid (GABA) receptor, has been studied primarily as an adjuvant for 
neuraxial anesthesia. Addition of preservative-free midazolam to 0.5% hyperbaric 
bupivacaine for subarachnoid block in infraumbilical surgery has been found to 
prolong the duration of effective analgesia as compared to the same concentra-
tion of bupivacaine alone and delays the need for postoperative rescue analgesics 
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without having any reported significant side effects or hemodynamic instability. 
The use of intrathecal midazolam also decreases the incidence of postoperative nau-
sea and vomiting. A small diluted intrathecal dose (1–2.5 mg) of preservative-free 
midazolam is reported to have few systemic side effects and is free of short-term 
neurotoxicity [49]. An infusion of epidural midazolam at 10–20 μg/kg/h for up to 
12 h is considered safe.
8.3 Neostigmine
Neostigmine is an acetylcholinesterase inhibitor that can enhance analgesia by 
acting on muscarinic receptors and increasing endogenous acetylcholine at the 
nerve terminal. It produces spinal analgesia in the preclinical models. Intrathecal 
neostigmine produces analgesia by the inhibition of (endogenous spinal neu-
rotransmitter) acetylcholine destruction via muscarinic and cholinergic receptors 
located at dorsal horn of spinal cord, substantia gelatinosa, and in lesser amounts 
at laminae III and V [50]. There is a high incidence of nausea and vomiting and 
prolongation of recovery from spinal anesthesia following intrathecal administra-
tion of neostigmine, implying that it may not be a useful additive for ambulatory 
spinal anesthesia. The dose of intrathecal neostigmine ranges from 10 to 50 μg with 
the side effects increasing as the dose rises.
8.4 Magnesium sulfate
Magnesium is an N-methyl-D-aspartate (NMDA) antagonist that plays a role in 
moderating calcium influx into neurons. Research has demonstrated that magne-
sium decreases peripheral nerve excitability and enhances the ability of lidocaine to 
raise the excitation threshold of A-beta fibers.
Intrathecal and epidural use of magnesium has shown variable results. It may 
prolong LA/opioid block in women in labor at a dose of 50 mg, but a very high dose 
of magnesium has been reported to produce transient neurological toxicity [17]. 
Farzanegan et al. compared the combination of bupivacaine 12.5 mg and morphine 
2 mg versus bupivacaine 12.5 mg and morphine 2 mg and magnesium 50 mg versus 
placebo epidurally for postoperative analgesia after thoracotomy. These authors 
achieved better analgesia and lower consumption of postoperative morphine 
significantly in the magnesium group [51]. In preeclamptic parturients doses of 
50 mg of intrathecal magnesium with epidural ropivacaine significantly prolonged 
postoperative analgesia compared with 1 mg intrathecal midazolam without any 
complications [52]. In a recent meta-analysis, 11 studies showed that the use of 
epidural magnesium as an adjuvant to bupivacaine is still controversial. Although 
epidural magnesium prolonged the time of the first rescue analgesic and reduced 
the number of patients who required rescue analgesics, as well as the requirement of 
these analgesics, further studies are needed to assess their usefulness [53].
8.5 Sodium bicarbonate
Local anesthetic agents are usually packed at low pH to enhance their shelf 
life. In anesthetic practice, there has been considerable interest in studying the 
effect of pH on the onset, duration, and potency of blockade of LAs. It is proven 
that alkalinization of the LA improves the quality of block by influencing the 
portioning coefficient of anesthetic between aqueous solution and biological 
membranes [20]. Adding sodium bicarbonate to lidocaine decreases the latency of 
onset and enhances the depth of epidural blockade by increasing the concentration 
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of non-ionized drug. The alkaline pH increases the extraneural amount of non-
ionized LA, which is the form that diffuses through the lipid phase of the neural 
membrane leading to more rapid diffusion across perineural tissue barriers [54]. 
CO2 produced by the addition of bicarbonate and bicarbonate per se reduces the 
margin of conduction safety of the neural membrane. Moreover, CO2 penetrates 
into the nerve, where it may determine trapping of the active cationic form of LA by 
acidifying the axoplasm [55].
8.6 Potassium chloride
Movements of ions through the nerve membrane are considered one of the main 
steps in the process of excitation and propagation of nerve stimuli. A nerve impulse 
can be effectively blocked by accumulation of potassium ions outside the neuron 
[56]. Thus, administration of exogenous potassium chloride will reinforce and 
prolong the blockade produced by LA. The addition of potassium chloride to LA 
increases the extracellular concentration and depolarizes the nerve membrane and 
thus blocks the conduction of nerve impulses. Potassium chloride up to 4 mmol/l to 
isotonic solutions of lidocaine enhances the clinical effectiveness of the combina-
tion [57]. The addition of physiological amounts of potassium chloride shortens the 
latency period and prolongs the duration of the blockade.
8.7 Adenosine
Adenosine receptors are expressed on the surface of most cells. Five classes of 
adenosine receptors have been identified. The A1 and A2 receptors are present 
centrally and peripherally, with agonism of the A1 receptor leading to antinocicep-
tive response and that of the A2 receptor being algogenic (i.e., activation results in 
pain). The diagnostic and therapeutic role for intrathecal adenosine in acute and 
chronic pain states is under investigation by several research groups. Intrathecal 
adenosine decreases the spontaneous and evoked pain intensity in patients with 
neuropathic pain involving hyperalgesia/dysesthesia/allodynia [58]. Its interaction 
along with spinal LA is just beginning to be studied.
8.8 Dextran
Low molecular weight dextran (LMWD) was used as an adjuvant with LA 
as early as in the 1970s, but the efficacy of dextrans including LMWD remained 
controversial, as several studies reported an absence of any substantial difference 
in analgesic duration with their addition. That might have been due to poor tech-
niques of regional anesthesia. The use of USG regional blocks has rekindled the use 
of LMWD as adjuvant. The addition of LMWD to a LA and epinephrine mixture 
when used as an infiltration anesthesia [59], or to a LA alone when performing 
a regional block [33], safely prolongs the effective action by reducing systemic 
absorption. More studies need to be conducted to elicit the exact mechanism and 
dosing ranges.
A word of caution regarding the use of additives in LAs is that only preparations 
without preservatives should be used, since these can be neurotoxic. Also, only 
adjuvants in clinically safe doses should be used in order to avoid getting the side 
effects due to excessive dosages.
Hence further research is required to find the exact mechanism of action and 
the safe dose of various adjuvants in order to avoid cardiovascular and neurological 
complications. The practice of making off-label use of drugs without getting FDA 
approval should be discouraged.
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9. Conclusion
Locoregional anesthesia is increasingly used as it has demonstrated efficacy, 
safety, and low costs. Patients and surgeons have realized its enormous advantages. 
Although the use of LA in the management of locoregional anesthesia, postopera-
tive pain, and chronic pain is limited by its duration of action and dose-dependent 
adverse effects that mainly affect the cardiovascular and CNS systems, this has been 
improved with the use of various LA adjuvant drugs. Adjuvants are medications 
that work synergistically with LAs to improve the onset, duration, and quality of 
anesthesia-analgesia in regional techniques, as well as greatly reducing the use of 
opioid analgesics.
The arsenal of adjuvants has developed from adrenaline, opioids, to a large 
group of non-opioid medications with various mechanisms of action. Opioids are 
the most commonly used adjuvants and range from morphine, fentanyl, and sufent-
anil to hydromorphone, buprenorphine, and tramadol with very different results. 
Its use has been limited by its adverse effects such as respiratory depression, nausea, 
vomiting, and pruritus, especially with its neuraxial use. Other adjuvants include 
alpha-2 agonists such as clonidine and dexmedetomidine, midazolam, NMDA 
antagonists including ketamine and magnesium, neostigmine, sodium bicarbonate, 
and nonsteroidal anti-inflammatory drugs. Concern regarding the safety profile of 
these adjuvants is due to their potential neurotoxicity and neurological complica-
tions that may limit their use and require further investigation.
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